# Taysha Gene Therapies, Inc.: overview TSHA · Nasdaq · CIK 1806310 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tsha.md) · [Financials](/companies/tsha/financials.md) · [Filings](/companies/tsha/filings.md) · [Insiders](/companies/tsha/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-344610.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-344610). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.8](/filings/0001193125-25-263506.md) | [2.0 d](/filings/0001193125-26-115202.md) | [2.3](/filings/0001193125-26-207666.md) | [2.0](/filings/0001193125-26-344610.md) | [0.0](/filings/0001193125-25-263506.md) | [5.5 d](/filings/0001193125-26-115202.md) | [0.0](/filings/0001193125-26-207666.md) | [0.0](/filings/0001193125-26-344610.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1448.4%)](/filings/0001193125-25-263506.md) | [(985.8%) d](/filings/0001193125-26-115202.md) | [(930.5%)](/filings/0001193125-26-207666.md) | [(1347.1%)](/filings/0001193125-26-344610.md) | not reported | [(516.0%) d](/filings/0001193125-26-115202.md) | not reported | not reported | | Net margin | % | [(1427.5%)](/filings/0001193125-25-263506.md) | [(929.0%) d](/filings/0001193125-26-115202.md) | [(935.2%)](/filings/0001193125-26-207666.md) | [(1353.6%)](/filings/0001193125-26-344610.md) | not reported | [(507.8%) d](/filings/0001193125-26-115202.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.10)](/filings/0001193125-25-263506.md) | not reported | [(0.08)](/filings/0001193125-26-207666.md) | [(0.09)](/filings/0001193125-26-344610.md) | [(0.09)](/filings/0001193125-25-263506.md) | not reported | [(0.12)](/filings/0001193125-26-207666.md) | [(0.13)](/filings/0001193125-26-344610.md) | | Free cash flow | $m | [(21.7) d](/filings/0001193125-25-263506.md) | [(18.3) d](/filings/0001193125-26-115202.md) | [(22.4)](/filings/0001193125-26-207666.md) | [(20.2) d](/filings/0001193125-26-344610.md) | [(24.3) d](/filings/0001193125-25-263506.md) | [(27.0) d](/filings/0001193125-26-115202.md) | [(40.9)](/filings/0001193125-26-207666.md) | [(40.4) d](/filings/0001193125-26-344610.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [2.5](/filings/0000950170-24-033484.md) | [15.5](/filings/0000950170-25-027348.md) | [8.3](/filings/0001193125-26-115202.md) | [9.8](/filings/0001193125-26-115202.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(6492.7%)](/filings/0000950170-24-033484.md) | [(468.8%)](/filings/0000950170-25-027348.md) | [(1097.6%)](/filings/0001193125-26-115202.md) | [(1130.6%)](/filings/0001193125-26-115202.md) | | Net margin | % | not reported | [(6635.3%)](/filings/0000950170-24-033484.md) | [(722.1%)](/filings/0000950170-25-027348.md) | [(1071.6%)](/filings/0001193125-26-115202.md) | [(1115.3%)](/filings/0001193125-26-115202.md) | | Diluted EPS | $ per share | [(4.64)](/filings/0000950170-23-010343.md) | [(3.78)](/filings/0000950170-24-033484.md) | [(0.96)](/filings/0000950170-25-027348.md) | [(0.36)](/filings/0001193125-26-115202.md) | [(0.34)](/filings/0001193125-26-115202.md) | | Free cash flow | $m | [(132)](/filings/0000950170-23-010343.md) | [(109)](/filings/0000950170-24-033484.md) | [(76.9)](/filings/0000950170-25-027348.md) | [(81.6)](/filings/0001193125-26-115202.md) | [(93.8)](/filings/0001193125-26-115202.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tsha/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $162.7m | 23,888,888 | | Added +2,188,888 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $160.4m | 23,555,648 | | Unchanged | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $154.7m | 22,713,118 | | Added +343,473 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $140.9m | 20,691,927 | | Added +2,326,319 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $132.2m | 19,415,000 | | Added +1,415,000 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $112.3m | 16,487,479 | | Reduced −1,477,892 | | [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $92.3m | 13,560,258 | | Reduced −119,990 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $90.8m | 13,336,413 | | Reduced −984,842 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $85.0m | 12,478,595 | | Added +2,247,093 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $77.8m | 11,421,920 | | Added +212,842 | ## Recent filings [All 400 filings](/companies/tsha/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:07 ET | [10-Q](/filings/0001193125-26-344610.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344610 | | 2026-08-11 | 16:05 ET | [8-K](/filings/0001193125-26-344594.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344594 | | 2026-06-25 | 16:26 ET | [8-K](/filings/0001193125-26-282855.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-282855 | | 2026-06-22 | 08:14 ET | [8-K](/filings/0001193125-26-276738.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-276738 | | 2026-06-02 | 16:05 ET | [8-K](/filings/0001193125-26-253478.md) | 5.07 Shareholder vote results | 0001193125-26-253478 | | 2026-05-06 | 08:30 ET | [10-Q](/filings/0001193125-26-207666.md) | Quarterly report, period 2026-03-31 | 0001193125-26-207666 | | 2026-05-06 | 08:11 ET | [8-K](/filings/0001193125-26-207633.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-207633 | | 2026-04-22 | 08:01 ET | [DEF 14A](/filings/0001193125-26-168525.md) | Proxy statement, period 2026-06-01 | 0001193125-26-168525 | | 2026-03-19 | 08:31 ET | [10-K](/filings/0001193125-26-115202.md) | Annual report, period 2025-12-31 | 0001193125-26-115202 | | 2026-03-19 | 08:08 ET | [8-K](/filings/0001193125-26-115177.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-115177 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-115202.md), filed Mar 19, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3b8e7b4c-ab58-4c3d-951c-821be968c7a2) ## About the filer - CIK: 1806310 - Tickers: TSHA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.